Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma
Quick Facts
- Publication title: Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma
- Journal: TRANSL LUNG CANCER R
- Year: 2022
- DOI: 10.21037/tlcr-21-729
- PMID/PMCID: 35529788; PMC9073734
Research overview
This study initially characterized the plasma exLR profile of early LUAD and reported on an exLR-based diagnostic signature for the detection of LUAD. This d-signature could be a promising noninvasive biomarker for the early detection and routine screening of LUAD.
Key findings
A diagnostic signature (d-signature) encompassing 8 exLR markers (NFKBIA, NDUFB10, SLC7A7, ARPC5, SEPTIN9, HMGN1, H4C2, and lnc-PLA2G1B-2:3) was identified for the detection of LUAD.
9 in the external validation group.
909, respectively, in the combined cohorts.
Study design
A case-control analysis was carried out involving 110 participants, including 64 stage I LUAD cases, 24 benign pulmonary nodule (BPN) cases, and 22 healthy controls (HCs).
The analysis was performed on the plasma samples' exLR profile based on exLR sequencing.
The d-signature was identified using the least absolute shrinkage and selection operator (LASSO) method and a training set (n=48), and validation was completed through use of an internal validation set (n=32) and an external validation set (n=30).
Echo Biotech Role
Echo Biotech contributed whole-transcriptome sequencing, lncRNA/mRNA sequencing.
Related platforms: Exoomics®
Related services and capabilities: EV lncRNA/mRNA Sequencing, EV Whole-Transcriptome Sequencing
References
Original publication: Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma Translational lung cancer research. 2022. DOI: 10.21037/tlcr-21-729. PMID/PMCID: 35529788; PMC9073734.